Literature DB >> 25455139

Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria.

Siyu Yan1, Wangqing Chen1, Shu Wen2, Wu Zhu1, Aiyuan Guo1, Xiaoping Chen3, Chong Zhang1, Mingliang Chen1, Jianglin Zhang1, Juan Su1, Yue Zhao1, Yijing He1, Zhaoqian Liu3, Honghao Zhou3, Weiqi Zeng1, Jie Li4, Xiang Chen5.   

Abstract

BACKGROUND: The nonsedating H1-antihistamines are the first-line medicines for chronic spontaneous urticaria (CSU) patients. However, not all these patients respond well to the antihistamines, and the mechanisms underlying the interindividual differences are still unclear. C5AR1 gene encodes the component 5a receptor (C5aR) protein, which has been reported to play an important role in chronic spontaneous urticaria.
OBJECTIVE: This study aimed to investigate whether the single nucleotide polymorphisms (SNPs) in C5AR1 are associated with CSU susceptibility and antihistamines therapeutic efficacy in Chinese CSU patients.
METHODS: A total of 191 CSU patients and 102 healthy controls were prospectively studied in our study. CSU patients were treated by nonsedating H1-antihistamines monotherapy for 4 weeks. The C5AR1 -1330T/G (rs11673309) genotype was determined by Sequenom Massarray.
RESULTS: Among these 191 CSU patients, there were 114 patients who were treated with desloratadine, 65 were treated with mizolastine, and 12 with fexofenadine. The-1330T alleles in CSU patients were significantly higher than controls (0.555 vs. 0.466, P=0.040, OR=1.429 [1.016-2.010]). The poorest response to desloratadine was observed in heterozygotes, when compared with either GG or TT homozgote (P=0.001). However, there was no significant difference in three genotypes when treated with mizolastine group (P=0.215).
CONCLUSION: We concluded that the C5AR1 SNP -1330T/G may serve as a useful pharmacodynamic predictor of nonsedating H1-antihistamines efficacy in CSU patients, and -1330T alleles may be taken as a risk factor for the CSU.
Copyright © 2014 Japanese Society for Investigative Dermatology. All rights reserved.

Entities:  

Keywords:  Antihistamines; C5AR1 polymorphism; Chronic spontaneous urticaria; Desloratadine; Mizolastine; UAS7

Mesh:

Substances:

Year:  2014        PMID: 25455139     DOI: 10.1016/j.jdermsci.2014.09.012

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

1.  [Clinical characteristics of urticaria in children versus adults].

Authors:  Ni Tang; Man-Yun Mao; Rui Zhai; Xiang Chen; Jiang-Lin Zhang; Wu Zhu; Jie Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

Review 2.  Immunoglobulin E-Mediated Autoimmunity.

Authors:  Marcus Maurer; Sabine Altrichter; Oliver Schmetzer; Jörg Scheffel; Martin K Church; Martin Metz
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

3.  Associations between vitamin D receptor gene polymorphisms and chronic spontaneous urticaria in Chinese Han population.

Authors:  Yiping Ma; Zhi Xiang; Xu Yao; Chengrang Li; Jianbing Wu; Suying Feng; Pangen Cui; Lin Lin
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

4.  Therapeutic effect of Bacillus Calmette-Guerin polysaccharide nucleic acid on mast cell at the transcriptional level.

Authors:  Siyu Yan; Runqiu Liu; Manyun Mao; Zhaoqian Liu; Wei Zhang; Yi Zhang; Jie Li; Cong Peng; Xiang Chen
Journal:  PeerJ       Date:  2019-08-21       Impact factor: 2.984

Review 5.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.